Research programme: RNAi-based hepatitis C virus therapeutics - Tacere TherapeuticsAlternative Names: OBP-701; RNAi HCV therapeutics - Tacere Therapeutics/Oncolys BioPharma; RNAi HCV therapeutics - Tacere Therapeutics/Pfizer; TT-033; TT-033i
Latest Information Update: 15 Jan 2013
At a glance
- Originator Benitec Ltd
- Developer Tacere Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis C